Man Group
CUE icon

Man Group’s Cue Biopharma CUE Stock Holding History

Man Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-372
Closed -$136K – 1979
2021
Q1 		$136K Buy
+372
New +$153K ﹤0.01% 1781

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's CUE Position: Q2 2021 in Review

Man Group sold out of Cue Biopharma (CUE) in Q2 2021, closing a stake of 372 shares — an estimated $136K sold.

Man Group first reported a position in CUE in Q1 2021 and held it in 1 quarter. The position peaked at $136K in Q1 2021. 89 funds tracked by Wall St. Rank hold CUE as of Q2 2021.

  • Man Group reported no remaining Cue Biopharma position as of Q2 2021 after selling out during the quarter.
  • Man Group sold 372 Cue Biopharma shares in Q2 2021, an estimated $136K.
  • Man Group first reported a position in Cue Biopharma in Q1 2021 and held it in 1 quarter.
  • Man Group's Cue Biopharma position peaked at $136K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2021.

Based on Man Group's 13F filing for Q2 2021, filed 16 Aug 2021.